Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQ001S vs Budesonide Suspension PK Study
NCT05148312Phase 1Completed
- Sponsor
- Aquilon Pharma
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of budesonide in asthma and chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Aquilon Pharma. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 8 more. Started Nov 2021; status: completed.
02
Drugs
budesonide
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05148312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148312.